Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research


PITTSBURGH, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth. Characterized by symptoms such as burning pain, white patches, swollen tissue, and open sores, OLP impacts approximately 6 million Americans and currently has no FDA-approved therapies.

Read this article:
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Related Posts